These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 15358999

  • 1. Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example.
    Elkin EB, Cowen ME, Cahill D, Steffel M, Kattan MW.
    Med Decis Making; 2004; 24(5):504-10. PubMed ID: 15358999
    [Abstract] [Full Text] [Related]

  • 2. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
    Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ.
    Cancer; 2007 Nov 15; 110(10):2210-7. PubMed ID: 17893907
    [Abstract] [Full Text] [Related]

  • 3. Prostate cancer screening: a decision analysis.
    Cantor SB, Spann SJ, Volk RJ, Cardenas MP, Warren MM.
    J Fam Pract; 1995 Jul 15; 41(1):33-41. PubMed ID: 7798064
    [Abstract] [Full Text] [Related]

  • 4. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
    Shimizu F, Igarashi A, Fukuda T, Kawachi Y, Minowada S, Ohashi Y, Fujime M.
    Jpn J Clin Oncol; 2007 Oct 15; 37(10):763-74. PubMed ID: 17956899
    [Abstract] [Full Text] [Related]

  • 5. Do older men benefit from curative therapy of localized prostate cancer?
    Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD.
    J Clin Oncol; 2003 Sep 01; 21(17):3318-27. PubMed ID: 12947068
    [Abstract] [Full Text] [Related]

  • 6. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.
    Mold JW, Holtgrave DR, Bisonni RS, Marley DS, Wright RA, Spann SJ.
    J Fam Pract; 1992 May 01; 34(5):561-8. PubMed ID: 1578205
    [Abstract] [Full Text] [Related]

  • 7. Use of nomograms for personalized decision-analytic recommendations.
    Fu AZ, Cantor SB, Kattan MW.
    Med Decis Making; 2010 May 01; 30(2):267-74. PubMed ID: 19648535
    [Abstract] [Full Text] [Related]

  • 8. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
    McNaughton-Collins M, Walker-Corkery E, Barry MJ.
    J Natl Cancer Inst Monogr; 2004 May 01; (33):78-101. PubMed ID: 15504921
    [Abstract] [Full Text] [Related]

  • 9. Predicting utility ratings for joint health States from single health States in prostate cancer: empirical testing of 3 alternative theories.
    Dale W, Basu A, Elstein A, Meltzer D.
    Med Decis Making; 2008 May 01; 28(1):102-12. PubMed ID: 18057188
    [Abstract] [Full Text] [Related]

  • 10. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
    Johansson E, Bill-Axelson A, Holmberg L, Onelöv E, Johansson JE, Steineck G, Scandinavian Prostate Cancer Group Study No 4.
    Eur Urol; 2009 Feb 01; 55(2):422-30. PubMed ID: 18783877
    [Abstract] [Full Text] [Related]

  • 11. A decision-analytic model for early stage breast cancer: lumpectomy vs mastectomy.
    Büyükdamgaci-Alogan G, Elele T, Hayran M, Erman M, Kiliçkap S.
    Neoplasma; 2008 Feb 01; 55(3):222-8. PubMed ID: 18348655
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
    Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y.
    Cancer; 2008 Mar 01; 112(5):1058-65. PubMed ID: 18186497
    [Abstract] [Full Text] [Related]

  • 13. Treatment decision-making strategies and influences in patients with localized prostate carcinoma.
    Gwede CK, Pow-Sang J, Seigne J, Heysek R, Helal M, Shade K, Cantor A, Jacobsen PB.
    Cancer; 2005 Oct 01; 104(7):1381-90. PubMed ID: 16080181
    [Abstract] [Full Text] [Related]

  • 14. Value of information on preference heterogeneity and individualized care.
    Basu A, Meltzer D.
    Med Decis Making; 2007 Oct 01; 27(2):112-27. PubMed ID: 17409362
    [Abstract] [Full Text] [Related]

  • 15. The cost of prostate cancer chemoprevention: a decision analysis model.
    Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y.
    Cancer Epidemiol Biomarkers Prev; 2006 Aug 01; 15(8):1485-9. PubMed ID: 16896037
    [Abstract] [Full Text] [Related]

  • 16. A novel computer based expert decision making model for prostate cancer disease management.
    Richman MB, Forman EH, Bayazit Y, Einstein DB, Resnick MI, Stovsky MD.
    J Urol; 2005 Dec 01; 174(6):2310-8. PubMed ID: 16280831
    [Abstract] [Full Text] [Related]

  • 17. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.
    Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR, Horwitz EM, Pollack A.
    Int J Radiat Oncol Biol Phys; 2006 Oct 01; 66(2):408-15. PubMed ID: 16887291
    [Abstract] [Full Text] [Related]

  • 18. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I, Coast J, Brown J.
    Pediatrics; 2005 May 01; 115(5):e600-14. PubMed ID: 15867026
    [Abstract] [Full Text] [Related]

  • 19. Measurement of quality of life in men with prostate cancer.
    Albaugh J, Hacker ED.
    Clin J Oncol Nurs; 2008 Feb 01; 12(1):81-6. PubMed ID: 18258577
    [Abstract] [Full Text] [Related]

  • 20. Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote.
    Denberg TD, Melhado TV, Steiner JF.
    Cancer; 2006 Aug 01; 107(3):620-30. PubMed ID: 16802287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.